Navigation Links
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
Date:7/5/2011

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"As more and more therapeutic agents are becoming available for non-small cell lung cancer therapy, selecting the best drug for each individual patient becomes increasingly challenging," said principal investigator Dr. Idris Bahce, of VU University Medical Center in Amsterdam, the Netherlands. "Predictive markers may offer guidance in personalizing therapy."

One marker that predicts tumor response to TKIs is the activating mutation of the epidermal growth factor receptor (EGFR) gene of the tumor cells, Dr. Bahce said. But it's not easy to obtain adequate tumor tissue from the patient for DNA analysis to determine whether the mutation exists.

In the study, non-small cell lung cancer (NSCLC) patients underwent PET (positron emission tomography) scans using radiolabeled erlotinib, a TKI.

"We found that patients who had an activating EGFR mutation also had an increased tracer uptake and were more sensitive to treatment with erlotinib as compared to those who did not have this mutation," Dr. Bahce said. "This is an important finding, as it indicates that this new imaging PET technique may be a non-invasive predictive marker that identifies NSCLC patients who benefit from treatment with TKIs."

Ten NSCLC patients, five with wild-type EGFR and five with activating EGFR mutations -- determined by DNA sequencing on tumor tissue -- were included in the study. Each was scanned twice using a procedure that included a low-dose computed tomography (CT) scan, a 10 minute [15O]water dynamic PET scan and a one-hour [11C]erlotinib dynamic PET scan.

Tumor uptake of [11C]erlotinib was significantly higher in the mutated group (median uptake (VT) = 1.70; range 1.33-2.30) than in the wild-type group (median uptake (VT) = 1.18; range, 0.75-1.34; p = 0.03). This difference was not due to differences in tumor perfusion. Tracer [11C]erlotinib uptake correlated with tumor response to subsequent erlotinib treatment, as only high-uptake tumors responded to treatment.


'/>"/>

Contact: Renee McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New Website Provides Counselors with Instant Help for Troubled Kids
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
4. Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson
5. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
6. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
7. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. MarquisNet Co-Location Agreement with MessageBroadcast Helps Message Delivery Provider Expand World-Class Network
10. Top Raleigh Dentist Robert Williamson Designated A Preferred Invisalign Provider
11. Save the Children Provides Songs with Lifesaving Health and Nutrition Advice to Haitian Radio Stations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: